David Nathaniel E 4
4 · Unity Biotechnology, Inc. · Filed May 7, 2018
Insider Transaction Report
Form 4
David Nathaniel E
DirectorPresident
Transactions
- Conversion
Common Stock
2018-05-07+1,074,032→ 2,054,878 total - Conversion
Common Stock
2018-05-07+222,148→ 2,277,026 total - Conversion
Common Stock
2018-05-07+1,630→ 2,278,656 total - Conversion
Series A-2 Preferred Stock
2018-05-07−1,074,032→ 0 total→ Common Stock (1,074,032 underlying) - Conversion
Series B Preferred Stock
2018-05-07−222,148→ 0 total→ Common Stock (222,148 underlying) - Conversion
Series C Preferred Stock
2018-05-07−1,630→ 0 total→ Common Stock (1,630 underlying)
Footnotes (2)
- [F1]The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.
- [F2]The expiration date is not relevant to the conversion of these securities.